Australia's most trusted
source of pharma news
Monday, 20 April 2026
Posted 20 April 2026 AM
The TGA has approved two new medicines - SOBI’s antibody-drug conjugate Zynlonta and Norgine’s antidote Pedmarqsi.
Zynlonta is provisionally approved for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.